Aykut Cilli1, Halid Bal1, Hakan Gunen2. 1. Department of Pulmonary Medicine, School of Medicine, Akdeniz University, Antalya, Turkey. 2. Sureyyapasa Research and Training Center for Chest Diseases and Thoracic Surgery, Medical Sciences University, Istanbul, Turkey.
Abstract
BACKGROUND: Roflumilast is the only phosphodiesterase enzyme 4 inhibitor approved in the treatment of chronic obstructive pulmonary disease (COPD) patients with chronic cough and sputum and a history of exacerbations. Real-world studies about the use of roflumilast are limited. Our aim was to assess the efficacy, safety and tolerability of roflumilast in the treatment of stable COPD, in a real-world setting. METHODS: From August 2014 to August 2017, medical records of all COPD patients who were prescribed roflumilast therapy in Akdeniz University Hospital were analyzed retrospectively. COPD patients were studied in terms of efficacy, safety, and drug discontinuation rate. Efficacy was evaluated as the effect of roflumilast on exacerbation and hospitalization rates of COPD compared to the pre-treatment period. RESULTS: Eighty-three COPD patients treated with roflumilast were included (mean age 66.2±9.3 years, 88.0% male). All the patients were chronic bronchitis and frequent exacerbator clinical phenotype and were classified in the Global Initiative for Chronic Obstructive Lung Disease categories C (n=17; 20.5%) and D (n=66; 79.5%). Mean duration of roflumilast use was 18.9±10.4 months. There was a significant decrease in both COPD exacerbations (2.7 vs. 1.16; P<0.001) and hospitalizations (0.77 vs. 0.32; P<0.001) in roflumilast users compared to the pre-treatment period. Of the patients, 22 (26.5%) experienced adverse events (AE) during their treatment period. The most frequently reported AEs were weight loss (10.8%), loss of appetite (10.8%) and nausea (8.4%). Serious or life-threatening AEs were not detected. Sixteen (19.3%) patients discontinued roflumilast because of AEs. CONCLUSIONS: Roflumilast reduced exacerbations and hospitalizations in our real-world population with severe COPD. AEs are common and frequently leading to discontinuation of roflumilast therapy.
BACKGROUND: Roflumilast is the only phosphodiesterase enzyme 4 inhibitor approved in the treatment of chronic obstructive pulmonary disease (COPD) patients with chronic cough and sputum and a history of exacerbations. Real-world studies about the use of roflumilast are limited. Our aim was to assess the efficacy, safety and tolerability of roflumilast in the treatment of stable COPD, in a real-world setting. METHODS: From August 2014 to August 2017, medical records of all COPD patients who were prescribed roflumilast therapy in Akdeniz University Hospital were analyzed retrospectively. COPD patients were studied in terms of efficacy, safety, and drug discontinuation rate. Efficacy was evaluated as the effect of roflumilast on exacerbation and hospitalization rates of COPD compared to the pre-treatment period. RESULTS: Eighty-three COPD patients treated with roflumilast were included (mean age 66.2±9.3 years, 88.0% male). All the patients were chronic bronchitis and frequent exacerbator clinical phenotype and were classified in the Global Initiative for Chronic Obstructive Lung Disease categories C (n=17; 20.5%) and D (n=66; 79.5%). Mean duration of roflumilast use was 18.9±10.4 months. There was a significant decrease in both COPD exacerbations (2.7 vs. 1.16; P<0.001) and hospitalizations (0.77 vs. 0.32; P<0.001) in roflumilast users compared to the pre-treatment period. Of the patients, 22 (26.5%) experienced adverse events (AE) during their treatment period. The most frequently reported AEs were weight loss (10.8%), loss of appetite (10.8%) and nausea (8.4%). Serious or life-threatening AEs were not detected. Sixteen (19.3%) patients discontinued roflumilast because of AEs. CONCLUSIONS: Roflumilast reduced exacerbations and hospitalizations in our real-world population with severe COPD. AEs are common and frequently leading to discontinuation of roflumilast therapy.
Authors: Erin Worndl; Eoin B Hunt; Marcus P Kennedy; Michael T Henry; Barry J Plant; Desmond M Murphy Journal: Chest Date: 2015-07 Impact factor: 9.410
Authors: Fernando J Martinez; Peter M A Calverley; Udo-Michael Goehring; Manja Brose; Leonardo M Fabbri; Klaus F Rabe Journal: Lancet Date: 2015-02-13 Impact factor: 79.321
Authors: Klaus F Rabe; Eric D Bateman; Denis O'Donnell; Stephan Witte; Dirk Bredenbröker; Thomas D Bethke Journal: Lancet Date: 2005 Aug 13-19 Impact factor: 79.321
Authors: Sang-Do Lee; David S C Hui; Aziah A Mahayiddin; Camilo C Roa; Kheng Hoe Kwa; Udo-Michael Goehring; Dirk Bredenbröker; Han-Pin Kuo Journal: Respirology Date: 2011-11 Impact factor: 6.424
Authors: Leonardo M Fabbri; Peter M A Calverley; José Luis Izquierdo-Alonso; Daniela S Bundschuh; Manja Brose; Fernando J Martinez; Klaus F Rabe Journal: Lancet Date: 2009-08-29 Impact factor: 79.321
Authors: Peter M A Calverley; Klaus F Rabe; Udo-Michael Goehring; Søren Kristiansen; Leonardo M Fabbri; Fernando J Martinez Journal: Lancet Date: 2009-08-29 Impact factor: 79.321
Authors: Peter M A Calverley; Fernando Sanchez-Toril; Andrew McIvor; Peter Teichmann; Dirk Bredenbroeker; Leonardo M Fabbri Journal: Am J Respir Crit Care Med Date: 2007-04-26 Impact factor: 21.405
Authors: Gema Requena; Achim Wolf; Rachael Williams; Daniel Dedman; Jennifer K Quint; Tarita Murray-Thomas; Jeanne M Pimenta Journal: Pharmacoepidemiol Drug Saf Date: 2021-01-09 Impact factor: 2.890
Authors: Karen Cowan; Graeme Macluskie; Michael Finch; Colin N A Palmer; Jane Hair; Max Bylesjo; Sarah Lynagh; Pamela Brankin; Marian McNeil; Carolyn Low; David Mallinson; Elaine M Gourlay; Hannah Child; Linda Cheyne; David C Bunton Journal: PLoS One Date: 2019-12-20 Impact factor: 3.240